Patents by Inventor Kristian Berg

Kristian Berg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230314441
    Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, therapies that utilize cancer biomarkers. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies.
    Type: Application
    Filed: October 14, 2022
    Publication date: October 5, 2023
    Inventors: Anette Weyergang, Maria Eb Berstad, Kristian Berg, Olav Engebraten
  • Publication number: 20230184777
    Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, therapies that utilize cancer biomarkers. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 15, 2023
    Inventors: Anette Weyergang, Maria Eb Berstad, Kristian Berg, Olav Engebraten
  • Patent number: 11506668
    Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, therapies that utilize cancer biomarkers. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: November 22, 2022
    Inventors: Olav Engebråten, Maria Eb Berstad, Kristian Berg, Anette Weyergang
  • Publication number: 20210121570
    Abstract: The invention provides mitochondria-targeted chemiluminescent agents and their use in methods of photodynamic therapy (PDT). In particular, the invention provides compounds of general formula (I), and their pharmaceutically acceptable salts: (I) in which A represents a chemiluminescent moiety; each L, which may be the same or different, is either a direct bond or a linker; each B, which may be the same or different, represents a mitotropic moiety; n is an integer from 1 to 3, preferably 1; and x is an integer from 1 to 3, preferably 1. Such compounds find particular use in the treatment of deeply-sited tumours, e.g. glioblastoma multiforme (GBM), when used in combination with a photosensitizer or photosensitizer precursor.
    Type: Application
    Filed: June 21, 2018
    Publication date: April 29, 2021
    Inventors: Georgios C. VOUGIOUKALAKIS, Georgios ROTAS, Theodossis A. THEODOSSIOU, Kristian BERG, Ángel Miranda Alonso MIGUEL
  • Publication number: 20200182879
    Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, therapies that utilize cancer biomarkers. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies.
    Type: Application
    Filed: June 22, 2018
    Publication date: June 11, 2020
    Inventors: Olav ENGEBRÅTEN, Maria Eb BERSTAD, Kristian BERG, Anette WEYERGANG
  • Patent number: 9901636
    Abstract: The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitizing agent, and uses thereof in photochemical internalization (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: February 27, 2018
    Assignee: PCI BIOTECH AS
    Inventors: Kristian Berg, Anders Hogset, Mar Masson, Vivek S. Gaware
  • Patent number: 9737594
    Abstract: The present invention provides a method of stimulating an immune response to an antigenic molecule, by contacting a cell with the antigenic molecule and with a photosensitizing agent, irradiating the cell, and thereby presenting the antigenic molecule, or part thereof, on the surface of said cell and stimulating an immune response.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: August 22, 2017
    Assignee: PCI Biotech AS
    Inventors: Kristian Berg, Torunn E. Tjelle, Anders Hogset, Lina Prasmickaite
  • Patent number: 9241996
    Abstract: The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: January 26, 2016
    Assignee: PCI BIOTECH AS
    Inventors: Anders Høgset, Anette Weyergang, P{dot over (a)}l Kristian Selbo, Kristian Berg
  • Publication number: 20150202293
    Abstract: The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitising agent, and uses thereof in photochemical internalisation (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.
    Type: Application
    Filed: May 14, 2013
    Publication date: July 23, 2015
    Applicant: PCI BIOTECH AS
    Inventors: Kristian Berg, Anders Hogset, Mar Masson, Vivek S. Gaware
  • Publication number: 20130330363
    Abstract: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.
    Type: Application
    Filed: July 5, 2012
    Publication date: December 12, 2013
    Applicant: PCI Biotech AS
    Inventors: Kristian Berg, Torunn E. Tjelle, Anders Hogset, Lina Prasmickaite
  • Patent number: 8216587
    Abstract: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: July 10, 2012
    Assignee: PCI Biotech AS
    Inventors: Kristian Berg, Torunn E. Tjelle, Anders H øgset, Lina Prasmickaite
  • Patent number: 8096419
    Abstract: The present invention provides photosensitizing agents obtained by reducing a single double bond in the porphyrin macrocycle of a sulphonated meso-tetraphenylporphyrin, preferably a disulphonated meso-tetraphenylporphyrin such as TPPS2a. The resulting sulphonated meso-tetraphenyl chlorins include compounds of formula I: (wherein X is —SO3H; n, p, q and r are each independently 0 or 1; and the sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, e.g. 2 or 4) isomers and isomer mixtures thereof. The compounds of the invention and their pharmaceutically acceptable salts find particular use as photosensitizing agents in the photochemical internalization of molecules and in photodynamic therapy.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: January 17, 2012
    Assignee: PCI Biotech AS
    Inventors: Claude Rimington, Greta Rimington, legal representative, Kristian Berg, Diem Thuy Thi Tran, Pal Kristian Selbo
  • Publication number: 20110293575
    Abstract: The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect.
    Type: Application
    Filed: June 26, 2009
    Publication date: December 1, 2011
    Applicant: PCI BIOTECH AS
    Inventors: Anders Høgset, Anette Weyergang, Pål Kristian Selbo, Kristian Berg
  • Patent number: 8008077
    Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: August 30, 2011
    Assignee: PCI Biotech AS
    Inventors: Kristian Berg, Lina Prasmickaite, Anders Hogset, Pal Kristian Selbo
  • Publication number: 20100121255
    Abstract: The present invention provides photosensitizing agents obtained by reducing a single double bond in the porphyrin macrocycle of a sulphonated meso-tetraphenylporphyrin, preferably a disulphonated meso-tetraphenylporphyrin such as TPPS2a. The resulting sulphonated meso-tetraphenyl chlorins include compounds of formula I: (wherein X is —SO3H; n, p, q and r are each independently 0 or 1; and the sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, e.g. 2 or 4) isomers and isomer mixtures thereof. The compounds of the invention and their pharmaceutically acceptable salts find particular use as photosensitizing agents in the photochemical internalization of molecules and in photodynamic therapy.
    Type: Application
    Filed: January 19, 2010
    Publication date: May 13, 2010
    Applicant: THE NORWEGIAN RADIUM HOSPITAL RESEARCH FOUNDATION
    Inventors: Claude Rimington, Greta Rimington, Kristian Berg, Diem Thuy Thi Tran, Pal Kristian Selbo
  • Patent number: 7662807
    Abstract: The present invention provides photosensitizing agents obtained by reducing a single double bond in the porphyrin macrocycle of a sulphonated meso-tetraphenylporphyrin, preferably a disulphonated meso-tetraphenylporphyrin such as TPPS2a. The resulting sulphonated meso-tetraphenyl chlorins include compounds of formula (I) (wherein X is —SO3H; n, p, q and r are each independently 0 or 1; and the sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, e.g. 2 or 4) isomers and isomer mixtures thereof. The compounds of the invention and their pharmaceutically acceptable salts find particular use as photosensitizing agents in the photochemical internalization of molecules and in photodynamic therapy.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: February 16, 2010
    Assignee: The Norwegian Radium Hospital Research Foundation
    Inventors: Claude Rimington, Greta Rimington, legal representative, Kristian Berg, Diem Thuy Thi Tran, Pal Kristian Selbo
  • Patent number: 7521239
    Abstract: A method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitizing agent, the cell is irradiated with light of a wavelength effective to activate the photosensitizing agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.
    Type: Grant
    Filed: November 29, 2001
    Date of Patent: April 21, 2009
    Assignee: PCI Biotech AS
    Inventors: Anders Høgset, Kristian Berg, Gunhild Mari Mælandsmo, Birgit Øvstebø Engesæter, Lina Prasmickaite
  • Publication number: 20070274953
    Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.
    Type: Application
    Filed: May 9, 2007
    Publication date: November 29, 2007
    Applicant: PCI BIOTECH AS
    Inventors: Kristian BERG, Lina PRASMICKAITE, Anders HOGSET, Pal SELBO
  • Patent number: 7223600
    Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosentistising agent, the cell is irradiated with light of a wavelength effective to activate the photosentisitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.
    Type: Grant
    Filed: November 29, 2001
    Date of Patent: May 29, 2007
    Assignee: The Norwegian Radium Hospital Research Foundation
    Inventors: Kristian Berg, Lina Prasmickaite, Anders Høgset, Pål Kristian Selbo
  • Publication number: 20060052433
    Abstract: The present invention provides photosensitizing agents obtained by reducing a single double bond in the porphyrin macrocycle of a sulphonated meso-tetraphenylporphyrin, preferably a disulphonated meso-tetraphenylporphyrin such as TPPS2a. The resulting sulphonated meso-tetraphenyl chlorins include compounds of formula (I) (wherein X is —SO3H; n, p, q and r are each independently 0 or 1; and the sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, e.g. 2 or 4) isomers and isomer mixtures thereof. The compounds of the invention and their pharmaceutically acceptable salts find particular use as photosensitizing agents in the photochemical internalization of molecules and in photodynamic therapy.
    Type: Application
    Filed: August 30, 2002
    Publication date: March 9, 2006
    Inventors: Kristian Berg, Diem Thuy Tran, Pal Selbo